NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 2026-10-07 15:09இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Aarey Drugs & Pharmaceuticals approved the allotment of 11,50,000 equity shares of face value ₹10 each following the conversion of warrants on September 30, 2026. The company collected ₹5.50 crore (representing the remaining 75% payment at ₹47.85 per warrant on an issue price of ₹63.80). This increases the paid-up share count from 3,07,24,303 to 3,18,74,303 shares, representing an equity dilution of approximately 3.7%. Across both tranches, 35,20,000 warrants have now been converted out of the total 50,00,000 warrants issued, leaving 14,80,000 warrants outstanding.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe board approved conversion of 11.50 lakh warrants into equity shares, raising ₹5.50 crore in cash and expanding the paid-up capital base to 3.19 crore shares.
ஏன் இது முக்கியம்Provides fresh equity funding to support working capital or capex projects, though it causes mild equity dilution (~3.7% in this tranche).
Shares allotted: 11,50,000Issue price per warrant: Rs. 63.80Amount raised in tranche: Rs. 5,50,27,500Fundraise vs Market Cap: ~1.8%Warrants outstanding: 14,80,000
📅 குறுகிய காலம்Neutral trading impact as warrant conversions at predetermined prices are routine corporate actions.
📈 நீண்ட காலம்Supports balance sheet strength and capital expenditure plans; slight dilution will be absorbed if ongoing capacity expansion delivers targeted earnings growth.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~3.7% from this tranche, with an additional 14.8 lakh warrants still eligible for conversion
Issue price of ₹63.80 represents a discount to the current market price of ₹107.8
👀 கவனிக்க வேண்டியவை
Track the deployment of funds toward ongoing API capex and monitor the remaining 14,80,000 warrants expiring within 18 months of their May 23, 2025 allotment.
Aarey Drugs Promoters Convert 25.2 Lakh Warrants; Share Capital Expands to 3.19 Cr Shares
Aarey Drugs and Pharmaceuticals disclosed insider warrant conversions by members of the promoter and promoter group as of September 30, 2026. Across the conversion stages, promoter group entities converted over 25.2 lakh warrants into equity shares, raising promoter group equity holding to 1,32,12,443 shares (41.45% of expanded voting capital). The total equity share capital expanded from 2,83,54,303 shares to 3,18,74,303 shares, with total diluted share capital standing at 3,33,54,303 shares.
உச்சம் நம்பிக்கை
என்ன மாறியதுPromoter entities exercised warrant conversion rights, increasing their equity share count by 25.2 lakh shares and boosting company paid-up equity capital to 3.19 crore shares.
ஏன் இது முக்கியம்Warrant conversion brings equity cash inflow to help fund capex and reduces leverage, while causing equity dilution of ~12.4% over original pre-conversion equity share capital.
Warrants converted by promoters: 2520000Post-allotment total equity shares: 31874303Promoter holding post-conversion: 41.45%Diluted equity share capital: 33354303
📅 குறுகிய காலம்Neutral trading impact as warrant conversion was pre-approved, though increased share supply creates minor equity dilution.
📈 நீண்ட காலம்Promoter capital commitment reflects confidence, providing funding support for their Rs 24.43 Cr manufacturing expansion.
⚠ அபாய எச்சரிக்கைகள்
Equity base dilution for existing minority shareholders
Thin operational margins (1.64%-1.94%) leave little room for execution missteps on capex
👀 கவனிக்க வேண்டியவை
Track the utilization of warrant subscription proceeds toward the ongoing Rs 24.43 Cr API capacity expansion and monitor subsequent quarterly shareholding patterns for final fully diluted promoter holding.
Aarey Drugs Allots 25.2 Lakh Shares to Promoters via Warrant Conversion Worth ₹12.06 Cr
Aarey Drugs and Pharmaceuticals has disclosed warrant conversions under SEBI PIT regulations resulting in an allotment of 25,20,000 equity shares to promoter group members on September 30, 2026. The total transaction value across seven promoter entities stands at approximately ₹12.06 Cr, representing ~4.1% of the company's current market cap of ₹291 Cr. Key promoter members including Bina Ghatalia, Mihir Ghatalia, and Nimit Ghatalia converted warrants into equity shares, infusing equity capital into the business.
உச்சம் நம்பிக்கை
என்ன மாறியதுPromoters exercised 25,20,000 convertible warrants into equity shares across seven accounts as of September 30, 2026.
ஏன் இது முக்கியம்Warrant conversion brings ₹12.06 Cr in equity capital and signals promoter financial commitment, helping fund ongoing capex while slightly diluting non-promoter equity.
Total shares allotted: 25,20,000Total transaction value: ₹12.06 கோடிCapital infused vs Market cap: ~4.1%Allotment Date: 30-09-2026
📅 குறுகிய காலம்Marginally positive sentiment as promoters infuse cash by converting warrants, though equity base expands.
📈 நீண்ட காலம்Supports equity base expansion and provides funding flexibility for the company's ₹24.43 Cr API capacity expansion project.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution from warrant conversion
Thin operating profit margins (1.9% TTM)
👀 கவனிக்க வேண்டியவை
Monitor updated shareholding pattern filings to track total promoter percentage changes and upcoming quarterly results to check deployment of funds toward ongoing capex.
Aarey Drugs and Pharmaceuticals approved the allotment of 11,50,000 equity shares upon conversion of warrants on September 30, 2026. The conversion was completed at an issue price of ₹63.80 per warrant, with the receipt of the remaining 75% consideration totaling ₹5.50 crore (₹47.85 per warrant). This brings the company's total issued and paid-up share capital up from 3,07,24,303 shares to 3,18,74,303 shares. A total of 14,80,000 warrants remain outstanding for conversion from the original 50,00,000 warrant issue.
உச்சம் நம்பிக்கை
என்ன மாறியது11.5 lakh warrants were converted into equity shares, raising ₹5.50 crore in cash and expanding paid-up capital by 3.74%.
ஏன் இது முக்கியம்Provides incremental equity capital to support ongoing operations or capex, accompanied by a minor dilution in existing shareholding.
📅 குறுகிய காலம்Neutral; warrant conversions are expected events within the 18-month window and create modest equity dilution against fresh capital inflow.
📈 நீண்ட காலம்Strengthens net worth marginally and aids balance sheet liquidity to support API manufacturing expansions.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution for existing public shareholders
Further dilution pending from 14.80 lakh outstanding warrants
👀 கவனிக்க வேண்டியவை
Track the deployment of funds towards the company's planned ₹24.43 crore API capex and monitor the conversion status of the remaining 14.80 lakh warrants before November 2026.
Q1 Revenue Falls 56.3% YoY to Rs 44.63 Cr; Net Profit Declines 25.3% to Rs 1.02 Cr
Aarey Drugs & Pharmaceuticals reported a 56.3% YoY drop in Q1 FY27 revenue from operations to Rs 44.63 Cr compared to Rs 102.21 Cr in Q1 FY26. Profit Before Tax fell 70.2% YoY to Rs 0.52 Cr (Rs 51.56 lakhs) against Rs 1.73 Cr in the year-ago period. Net profit stood at Rs 1.02 Cr, down 25.3% YoY, supported by a deferred tax credit of Rs 0.81 Cr. Finance costs remained high at Rs 1.67 Cr, up 61.4% YoY.
உச்சம் நம்பிக்கை
என்ன மாறியதுAarey Drugs released its unaudited standalone financial results for Q1 ended June 30, 2026, marking a sharp sequential and YoY drop in top-line revenue.
ஏன் இது முக்கியம்A 56% top-line contraction combined with elevated finance costs puts severe pressure on pre-tax profitability, underscoring high revenue volatility in the bulk drugs business.
Reliance on deferred tax credits (Rs 0.81 Cr) to support PAT
👀 கவனிக்க வேண்டியவை
Track subsequent quarterly volume trends and the commercialization progress of the 26,000 MT API/bulk drug capex to assess operational recovery.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Rs 12.06 Cr raised by Aarey Drugs via conversion of 25.20 lakh warrants
Aarey Drugs & Pharmaceuticals has allotted 25.20 lakh equity shares following the conversion of warrants issued in May 2025. The company received Rs 12.06 crore, representing the final 75% payment of the Rs 63.80 issue price per warrant. The allottees are primarily from the promoter group (Ghatalia family), and the conversion results in an equity dilution of approximately 17.6%. This cash infusion is significant for a company with a TTM PAT of only Rs 4 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has converted a portion of its outstanding warrants into equity, resulting in a cash infusion of Rs 12.06 crore and an increase in the total number of outstanding shares.
ஏன் இது முக்கியம்For a small-cap company with thin operating margins (1.9%) and limited pricing power, this capital infusion (equivalent to 3x TTM PAT) provides essential liquidity for its ongoing Rs 24.43 crore expansion project.
📅 குறுகிய காலம்The stock may see neutral to positive sentiment as the cash infusion strengthens the balance sheet, though the equity dilution is now formalized.
📈 நீண்ட காலம்The conversion by promoters signals confidence in the business; however, long-term value depends on the successful operationalization of the 26,000 MT capacity expansion to improve thin margins.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution of ~17.6%
Thin operating margins (1.9%) leaving little room for error
High promoter concentration in the warrant conversion
👀 கவனிக்க வேண்டியவை
Investors should monitor if these proceeds are utilized to accelerate the Phase 2 CAPEX project (13,000 MT) scheduled for completion in August 2026 or to reduce the Rs 50 crore debt burden.
Aarey Drugs Reports FY26 Results; Total Assets Grow 17% to ₹211.24 Cr
Aarey Drugs & Pharmaceuticals Limited reported its audited financial results for the fiscal year ended March 31, 2026, showing a healthy expansion in its balance sheet. Total assets grew to ₹211.24 crore from ₹180.50 crore in the previous year, while total equity increased to ₹143.69 crore. The company received an unmodified audit opinion, although auditors noted that debtor and creditor balances are subject to confirmation. Additionally, the board reviewed the utilization of funds raised through the preferential issue of convertible warrants.
முக்கிய அம்சங்கள்
Total assets increased by 17% year-on-year to ₹211.24 crore as of March 31, 2026.Total equity (Share Capital + Other Equity) rose to ₹143.69 crore, up from ₹133.00 crore in FY25.Current assets, including trade receivables and inventories, reached ₹176.70 crore compared to ₹155.06 crore last year.The company received an unmodified audit opinion, ensuring the reliability of the reported financial figures.Board approved the statement of fund utilization for convertible warrants issued via the preferential route.
👀 கவனிக்க வேண்டியவை
Investors should focus on the upcoming Profit & Loss statement to evaluate margin trends and monitor the 'Emphasis of Matter' regarding the confirmation of debtor balances, which are significant to the current asset base.
Aarey Drugs & Pharmaceuticals Limited held a board meeting on February 11, 2026, to approve the unaudited financial results for the quarter ended December 31, 2025. The board confirmed the submission of the Limited Review Report and MD/CFO certifications as per SEBI regulations. The company operates in a single business segment, focusing on bulk drugs and chemical imports. While the specific profit and loss figures were not detailed in this cover letter, the results have been officially taken on record.
முக்கிய அம்சங்கள்
Board approved unaudited financial results for the quarter ended December 31, 2025.The board meeting was held on February 11, 2026, from 3:00 p.m. to 6:30 p.m.MD and CFO provided formal certification regarding the accuracy of the financial statements.The company confirmed it operates within a single reporting segment.
👀 கவனிக்க வேண்டியவை
Investors should look for the detailed financial tables on the stock exchange to evaluate revenue growth and margin performance. Monitor the company's ability to manage raw material costs in the bulk drug and solvent import business.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
